심방세동 환자에서의 뇌졸중 예방
Stroke Prevention in Atrial Fibrillation
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
It is important to evaluate the risks of stroke and bleeding when screening patients with atrial fibrillation (AF), in whom anticoagulation therapy is indicated. Oral anticoagulation therapy is recommended in male AF patients with CHA2 DS2-VASc score ≥1 and female AF patients with CHA2 DS2-VASc score ≥2. Non-vitamin K oral anticoagulants (NOACs) are preferred over vitamin K anticoagulants in eligible patients. NOACs are contraindicated in patients with mechanical heart valves or moderate-to-severe mitral stenosis.
Abstract
It is important to evaluate the risks of stroke and bleeding when screening patients with atrial fibrillation (AF), in whom anticoagulation therapy is indicated. Oral anticoagulation therapy is recommended in male AF patients with CHA2 DS2-VASc score ≥1 and female AF patients with CHA2 DS2-VASc score ≥2. Non-vitamin K oral anticoagulants (NOACs) are preferred over vitamin K anticoagulants in eligible patients. NOACs are contraindicated in patients with mechanical heart valves or moderate-to-severe mitral stenosis.
참고문헌 (10)
- January CT, "2014 AHA", ACC, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
- Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
- 정병천, "The Korean Heart Rhythm Society’s 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society", Korean Circulation Journal, 45(01), pp.9~19 (2015), 대한심장학회
- Wolf PA, "Atrial fibrillation as an independent risk factor for stroke : the Framingham Study", Stroke, 22, pp.983~988 (1991)
- Mason PK, "Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation", Am J Med, 125, pp.603.e1~603.e6 (2012)
- Tomita H, "Validation of Risk Scoring System Excluding Female Sex From CHA2DS2-VASc in Japanese Patients With Nonvalvular Atrial Fibrillation - Subanalysis of the J-RHYTHM Registry", Circ J, 79, pp.1719~1726 (2015)
- Lee SR, "Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population", Int J Cardiol, 236, pp.226~231 (2017)
- Chiang CE, "Stroke prevention in atrial fibrillation : an Asian perspective", Thromb Haemost, 111, pp.789~797 (2014)
- Lip GY, "Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal", Int J Cardiol, 180, pp.246~254 (2015)
- Chan YH, "Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation", J Am Coll Cardiol, 68, pp.1389~1401 (2016)